JAMA/ LinkedIn
Sep 1, 2025, 07:40
JAMA: Semaglutide and Tirzepatide Reduce Heart Failure Risk in Patients With HFpEF
Journal of the American Medical Association (JAMA) made a noteworthy post on LinkedIn:
“In patients with cardiometabolic HFpEF, semaglutide and tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide.”
Read the full article here:
Article: Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Nils Krüger, Sebastian Schneeweiss, Kenshiro Fuse, Sofiya Matseyko, Sushama Kattinakere Sreedhara, Georg Hahn, Heribert Schunkert, Shirley V. Wang
Follow the newest insights in hematology with Hemostasis Today.
-
Oct 26, 2026, 16:16Wendy Jean Schell: How Genetics and Supplements May Influence Bleeding Risk
-
Oct 26, 2026, 15:37Sally Mandour: Lupus Anticoagulant-The Tree Key Diagnostic Criteria
-
Oct 26, 2026, 15:37Aryabhatta Sadhu: Intrauterine Red-Cell and Platelet Transfusion in Fetal Medicine
-
Oct 26, 2026, 15:25Christine Tunkl: Telestroke – Expanding Access to Evidence-Based Stroke Care
-
Oct 26, 2026, 15:13Heghine Khachatryan: Approaching Thrombocytopenia Through Mechanism and Clinical Context
-
Oct 26, 2026, 15:03Quentin Eichbaum։ AABB 2026 Annual Meeting Personal Highlights
-
Oct 26, 2026, 14:57A Father’s Marathon Journey Inspired by His Son – National Bleeding Disorders Foundation
-
Oct 26, 2026, 14:48Fran Huelsmeyer: The Clinical Importance of Blood Donation in Maternal Care
-
Oct 26, 2026, 14:45Maria Elisa Mancuso: Shaping the Future of Hemophilia Care with Patients